Hypophysitis: Evaluation and Management

被引：67
作者：
Faje A. [1 ]
机构：
[1] Massachusetts General Hospital and Harvard Medical School, Neuroendocrine Unit, 55 Fruit Street, Boston, 02114, MA
来源：
Clinical Diabetes and Endocrinology | / 2卷 / 1期
关键词：
Diabetes insipidus; Hypophysitis; Hypopituitarism;
D O I：
10.1186/s40842-016-0034-8
中图分类号：
学科分类号：
摘要：
Hypophysitis is the acute or chronic inflammation of the pituitary gland. The spectrum of hypophysitis has expanded in recent years with the addition of two histologic subtypes and recognition as a complication of treatment with immune checkpoint inhibitors. Despite the increased number of published cases, the pathogenesis of hypophysitis is poorly understood, and treatment strategies are diverse and controversial. The diagnosis of hypophysitis generally requires histopathologic confirmation. The presentation and clinical course of hypophysitis varies. Hypophysitis can resolve spontaneously, relapse may occur, and some cases can be refractory to treatment. © 2016 The Author(s).
引用
收藏
相关论文
共 105 条
[91]  
Lupi I., Broman K.W., Tzou S.C., Gutenberg A., Martino E., Caturegli P., Novel autoantigens in autoimmune hypophysitis, Clin Endocrinol (Oxf), 69, pp. 269-278, (2008)
[92]  
Smith C.J., Bensing S., Burns C., Robinson P.J., Kasperlik-Zaluska A.A., Scott R.J., Kampe O., Crock P.A., Identification of TPIT and other novel autoantigens in lymphocytic hypophysitis: immunoscreening of a pituitary cDNA library and development of immunoprecipitation assays, Eur J Endocrinol, 166, pp. 391-398, (2012)
[93]  
Falorni A., Minarelli V., Bartoloni E., Alunno A., Gerli R., Diagnosis and classification of autoimmune hypophysitis, Autoimmun Rev, 13, pp. 412-416, (2014)
[94]  
Ricciuti A., Remigis A., Landek-Salgado M.A., Vincentiis L., Guaraldi F., Lupi I., Iwama S., Wand G.S., Salvatori R., Caturegli P., Detection of pituitary antibodies by immunofluorescence: approach and results in patients with pituitary diseases, J Clin Endocrinol Metab, 99, pp. 1758-1766, (2014)
[95]  
Wallace Z.S., Stone J.H., An update on IgG4-related disease, Curr Opin Rheumatol, 27, pp. 83-90, (2015)
[96]  
Vidarsson G., Dekkers G., Rispens T., IgG subclasses and allotypes: from structure to effector functions, Front Immunol, 5, (2014)
[97]  
Iwama S., Remigis A., Callahan M.K., Slovin S.F., Wolchok J.D., Caturegli P., Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody, Sci Transl Med, 6, (2014)
[98]  
Romano E., Kusio-Kobialka M., Foukas P.G., Baumgaertner P., Meyer C., Ballabeni P., Michielin O., Weide B., Romero P., Speiser D.E., Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients, Proc Natl Acad Sci U S A, 112, pp. 6140-6145, (2015)
[99]  
Laurent S., Queirolo P., Boero S., Salvi S., Piccioli P., Boccardo S., Minghelli S., Morabito A., Fontana V., Pietra G., Et al., The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production, J Transl Med, 11, (2013)
[100]  
Faje A., Ma J., Wang X., Swearingen B., Tritos N.A., Nachtigall L., Zhang X., Klibanski A., Cytotoxic T-lymphocyte antigen-4 gene expression in human pituitary adenomas, (2015)
234567891011